{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:43:31Z","timestamp":1782020611080,"version":"3.54.5"},"reference-count":23,"publisher":"Hindawi Limited","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3669,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00592.x","type":"journal-article","created":{"date-parts":[[2005,8,15]],"date-time":"2005-08-15T16:30:15Z","timestamp":1124123415000},"page":"1091-1096","source":"Crossref","is-referenced-by-count":64,"title":["Lanthanum carbonate (Fosrenol\u00ae): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients"],"prefix":"10.1155","volume":"59","author":[{"given":"F.","family":"Albaaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2005,8,15]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200363060-00005","article-title":"Hyperphosphataemia in renal failure: causes, consequences and current management","volume":"63","author":"Albaaj","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB2|cit2","first-page":"217A","article-title":"Which causes of death are related to hyperphosphataemia in haemodialysis (HD) patients?","volume":"9","author":"Levine","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic haemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","article-title":"Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patients: recommendations for a change in management","volume":"35","author":"Block","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB5|cit5","first-page":"318","article-title":"Prevalence and clinical consequences of elevated Ca \u00d7 P product in haemodialysis patients","volume":"54","author":"Block","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB6|cit6","first-page":"243","article-title":"Hyperphosphataemia - a silent killer of patients with renal failure?","volume":"74","author":"Amann","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB8|cit8","unstructured":"The New Encyclopedia Britannica 7 2003: 152 3"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB9|cit9","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4684-8748-0","volume-title":"Biochemistry of the Lanthanides","author":"Evans","year":"1990"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB10|cit10","unstructured":"King RO Fricker SP. 1997"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000408063","article-title":"Gastrointestinal absorption of aluminium in chronic renal insufficiency","volume":"38","author":"Knoll","year":"1984","journal-title":"Contrib Nephrol"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00592.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/ndt\/gfh1004","article-title":"Improving phosphate-binder therapy as a way forward","volume":"19","author":"Hutchison","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB13|cit13","first-page":"227","article-title":"Studies of the ultra structure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers","volume":"184","author":"Xu","year":"1994","journal-title":"J Anat"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB14|cit14","first-page":"113","article-title":"Lanthanum carbonate: a novel non-calcaemic phosphate binder in dialysis patients","volume":"15","author":"Hutchison","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB15|cit15","first-page":"261A","article-title":"Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis","volume":"10","author":"Finn","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate. a new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000084653","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomised, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14656566.6.2.319","article-title":"Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients","volume":"6","author":"Albaaj","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/ndt\/gfh282","article-title":"Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate","volume":"19","author":"Hutchison","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB20|cit20","unstructured":"Shire pharmaceuticals. 2001"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00592.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (FosrenolR) and calcium carbonate on renal bone disease in dialysis patients","volume":"63","author":"D'Haese","year":"2003","journal-title":"Kidney Int"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00592.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfh1003","article-title":"Improving outcome of hyperphosphataemia","volume":"19","author":"De Broe","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1368-5031.2005.00592.x-BIB23|cit23","first-page":"764A","article-title":"One-year, randomized, open-label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol) and calcium carbonate in dialysis patients","volume":"14","author":"Torres","year":"2003","journal-title":"J Am Soc Nephrol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00592.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00592.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:47Z","timestamp":1643349947000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00592.x"}},"subtitle":["LANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATAEMIA"],"short-title":[],"issued":{"date-parts":[[2005,8,15]]},"references-count":23,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00592.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8,15]]}}}